The relationship between prolonged antiretroviral therapy and cryptogenic liver disease

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 5, 2009, Pages 554-556

  Stebbing, Justin ^a   Wong, Nick ^a   Tan, Lionel ^a   Scourfield, Andrew ^a   Jiao, Long ^a   Shousha, Sami ^a   Grover, Deepa ^a   Bower, Mark ^a   Nelson, Mark ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

BILE DUCT DISEASE; CHRONIC HEPATITIS; ENZYME BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAHEPATIC THROMBOSIS; LETTER; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER HYPERPLASIA; PRIORITY JOURNAL; SCLEROSING CHOLANGITIS; VIRUS LOAD; ADULT; AGED; DRUG ADMINISTRATION; FEMALE; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; TOXIC HEPATITIS;

ADULT; AGED; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS, CHRONIC, DRUG-INDUCED; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 65449186256     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31819c338f     Document Type: Letter

References (12)

1. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005;34:121-130.
2. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatology. 2005;42: 799-805.
3. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
4. Maida I, Nunez M, Rios MJ, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr. 2006;42:177-182.
5. Caldwell S, Oelsner D, Iezzoni J, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664-669.
6. Maida I, Garcia-Gasco P, Sotgui G, et al. HIV associated hepatopathyda new clinical condition: prevalence, eitiology and outcome. Presented at: 3rd International Workshop on HIV and Hepatitis co-infection; June 7-9, 2007; Paris, France. Abstract 45.
7. Colina F, Alberti N, Solis JA, et al. Diffuse nodular regenerative hyperplasia of the liver (DNRH). A clinicopathologic study of 24 cases. Liver. 1989;9:253-265.
8. Mallet V, Blanchard P, Verkarre V, et al. Nodular regenerative hyperplasia is a newcause of chronic liver disease in HIV infected patients. AIDS. 2007;21:187-192.
9. Sandrine PF, Sylvie A, André E, et al. Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect? AIDS. 2007;21: 1498-1499.
10. Arey B, Markov M, Ravi J, et al. Nodular regenerative hyperplasia of liver as a consequence of ART. AIDS. 2007;21:1066-1068.
11. Garvey LJ, Thomson EC, Lloyd J, et al. Response to Mallet et al., 'Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients'. AIDS. 2007; 21:1494-1495.
12. Pineda JA, Macías J. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy. J Antimicrob Chemother. 2005;55:417-419.